Literature DB >> 22833995

Microneedle delivery: clinical studies and emerging medical applications.

Ronald J Pettis1, Alfred J Harvey.   

Abstract

The concept of microneedle drug delivery was described three decades ago; however, effective clinical demonstration has only occurred within the past 10-15 years. Substantial progress in microneedle design and fabrication including extensive in vitro, ex vivo, and in vivo preclinical evaluation with various drugs, vaccines and other agents has transpired over the last decade. In contrast with this large volume of preclinical data, there are relatively few published microneedle clinical studies. To date, the clinical investigative focus has included testing to reduce dermal barrier properties and enhance transdermal delivery; evaluation of enhanced vaccine antigenicity, including development of the first commercial microneedle product for intradermal influenza vaccination; evaluation of altered microneedle protein pharmacokinetics and pharmacodynamics, especially for insulin; and evaluation of the pain and other perceptions associated with microneedle usage. This review summarizes the various aspects of microneedle clinical evaluation to date and identifies areas requiring further clinical evaluation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22833995     DOI: 10.4155/tde.12.13

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  18 in total

Review 1.  Effect of vaccine administration modality on immunogenicity and efficacy.

Authors:  Lu Zhang; Wei Wang; Shixia Wang
Journal:  Expert Rev Vaccines       Date:  2015-08-27       Impact factor: 5.217

2.  Challenges and Future Prospects for the Delivery of Biologics: Oral Mucosal, Pulmonary, and Transdermal Routes.

Authors:  Javier O Morales; Kristin R Fathe; Ashlee Brunaugh; Silvia Ferrati; Song Li; Miguel Montenegro-Nicolini; Zeynab Mousavikhamene; Jason T McConville; Mark R Prausnitz; Hugh D C Smyth
Journal:  AAPS J       Date:  2017-02-13       Impact factor: 4.009

3.  Evaluating the Impact of Human Factors and Pen Needle Design on Insulin Pen Injection.

Authors:  Christopher Rini; Bruce C Roberts; Didier Morel; Rick Klug; Benjamin Selvage; Ronald J Pettis
Journal:  J Diabetes Sci Technol       Date:  2019-03-17

4.  Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion.

Authors:  Elaine McVey; Laurence Hirsch; Diane E Sutter; Christoph Kapitza; Sibylle Dellweg; Janina Clair; Kerstin Rebrin; Kevin Judge; Ronald J Pettis
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

5.  The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.

Authors:  Nadine G Rouphael; Michele Paine; Regina Mosley; Sebastien Henry; Devin V McAllister; Haripriya Kalluri; Winston Pewin; Paula M Frew; Tianwei Yu; Natalie J Thornburg; Sarah Kabbani; Lilin Lai; Elena V Vassilieva; Ioanna Skountzou; Richard W Compans; Mark J Mulligan; Mark R Prausnitz
Journal:  Lancet       Date:  2017-06-27       Impact factor: 79.321

Review 6.  Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview.

Authors:  Nicola Luigi Bragazzi; Andrea Orsi; Filippo Ansaldi; Roberto Gasparini; Giancarlo Icardi
Journal:  Hum Vaccin Immunother       Date:  2016-05-31       Impact factor: 3.452

7.  Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity.

Authors:  Bao-Zhong Wang; Harvinder S Gill; Cheng He; Changbo Ou; Li Wang; Ying-Chun Wang; Hao Feng; Han Zhang; Mark R Prausnitz; Richard W Compans
Journal:  J Control Release       Date:  2014-01-11       Impact factor: 9.776

8.  Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitis.

Authors:  Mark K Slifka; Donald Y M Leung; Erika Hammarlund; Hans-Peter Raué; Eric L Simpson; Susan Tofte; Shahana Baig-Lewis; Gloria David; Henry Lynn; Rob Woolson; Tissa Hata; Henry Milgrom; Jon Hanifin
Journal:  J Allergy Clin Immunol       Date:  2013-12-10       Impact factor: 10.793

9.  Insulin (Technique) Induced Hypoglycaemia.

Authors:  Adlyne Reena Asirvatham; Shriraam Mahadevan; Balasubramaniam Sathish Kumar; Srinivas Devaganipalli Nrusimha; Thiagarajan Radhakrishnan Vadivel
Journal:  J Clin Diagn Res       Date:  2017-05-01

Review 10.  Nucleic acid delivery into skin for the treatment of skin disease: Proofs-of-concept, potential impact, and remaining challenges.

Authors:  Michael Zakrewsky; Sunny Kumar; Samir Mitragotri
Journal:  J Control Release       Date:  2015-09-15       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.